Rochester,NY 9/2/2009 12:01:10 AM
IsoRay, Inc. ISR, FDA Expanded Clearance for Proxcelan(TM) Cesium-131 Brachytherapy Seeds
IsoRay, Inc.
IsoRay, Inc. (ISR) has received clearance from the FDA for its Premarket Notification, 510(k)for Proxcelan(TM) Cesium-131 Brachytherapy Seeds enabling the company to preload Cesium-131 into flexible braided strands and surgical
mesh.
This FDA clearance allows IsoRay to market Cesium-131 seeds for use in the treatment of cancers well beyond the current prostate marke
This order clears the product for commercial distribution for treatment of lung and head and neck tumors as well as tumors in other organs. While Cesium-131 seeds themselves have been cleared for this indication since 2003, this current 510(k) allows Cesium-131 to be delivered in a new, convenient and sterile format that can be implanted without additional seed loading by the facility. The 510(k) also clears the application of the braided strands onto a bioabsorbable mesh matrix to further facilitate implant procedures.
About Stock Einstein
StockEinstein uses proprietary technologies coupled with years of experience to uncover stocks we feel have the greatest potential for breakout performance. We utilize not only software, but time tested criteria to uncover these potential winners. When these benchmarks are reached or exceeded, our subscribers are immediately notified.
This service is free and available only to subscribers. Scroll to the bottom of this page to signup for free stock alerts and visit our site.
Disclaimer: Full disclaimer at http://StockEinsteain.com/disclaimer.php
IMPORTANT: Never invest in any stock featured in any press release, email or website unless you can afford the loss of your entire investment. Stocks and particularly penny stocks have the possibility for dramatic gains, and also losses. Neither StockEinsteain, nor any of its affiliates are registered investment advisors or broker dealers.
